Navigation Links
Study Finds Discontinuation of Rosiglitazone Left Many Diabetes Patients Without Good Glycemic Control
Date:4/14/2009

JACKSONVILLE, Fla., April 14 /PRNewswire-USNewswire/ -- When concerns were raised about the safety of the diabetes medication, rosiglitazone, in May 2007, many patients and their doctors made the decision to discontinue use of the drug. A study published today in Endocrine Practice by Dr. Etta Fanning from the University of Texas Health Science Center along with her colleagues reported that many patients who discontinued use of rosiglitazone received less therapy and higher blood glucose levels as a result.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b)

A meta-analysis published in 2007 showed an increased risk of cardiovascular disease and myocardial infarction for patients using rosiglitazone. After that data was published, the FDA placed a black box warning on both thiazolidinediones (TZD) on the market, rosiglitazone and pioglitazone.

The study published in Endocrine Practice today entitled Clinical Practice Impact of Rosiglitazone Discontinuation on Glycemic Control shows that 89% of patients in the study group were using combination therapy before discontinuing use of rosiglitazone. After discontinuation, only 33% of patients were on a combination therapy. Another 13% of the group were not prescribed any diabetes medication at all.

The glycemic control of the group was also impacted after discontinuing rosiglitazone. In patients who received combination therapy, and who had laboratory values in both pre- and post-discontinuation periods, significant increases were observed in both fasting blood glucose and A1c.

In an accompanying Editorial, cardiologists Drs. Stuart Zarich and Dr. Richard Nesto, from Yale Medical School and L
'/>"/>

SOURCE American Association of Clinical Endocrinologists
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Study reports success in treating a rare retinal disorder
2. Low Blood Sugar Events Increase Dementia Risk in Elderly Patients With Type 2 Diabetes, Kaiser Permanente Study Finds
3. Avoiding No Mans Land: New Deloitte Study on Follow-on Biologics Investigates Proposed Legislation and Possible Unintended Consequences
4. Impotence Drugs Dont Harm Vision: Study
5. Three Medical Centers Awarded Funds to Study Generation of Cardiac Muscle Cells
6. National Physicians Study: Nearly One Third Would Choose Different Career Today
7. Ex-White House Drug Czar McCaffrey, U.S. Congress Drug Caucus Chair Cummings, CRC Health CEO Karlin Join Hopkins Researchers at News Conference April 17 on Breakthrough Study: Internet Video Drug Treatment as Effective as Traditional Counseling
8. Study of neighborhoods points to modifiable factors, not race, in cancer disparities
9. New alternative to biopsy detects subtle changes in cancer cells, Stanford study shows
10. Study Challenges Link Between Panic Attacks, PTSD
11. Study assesses new surgical procedure for regenerating cartilage in damaged knee joints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2010)... Will Connect Families with Uninsured Children to Non-Profit Agencies Assisting with Enrollment into State-Sponsored Health Coverage Programs , ... ... ... ... ST. PAUL, Minn. , March ...
(Date:3/16/2010)... the Superfruits Behind , ... Provo, UT (Vocus) March ... their flagship product will no longer be called Tahitian Noni® Juice, ... . Although the name is changing, Tahitian Noni Original is the ... people around the world for years. The name change comes from ...
(Date:3/16/2010)... Dr. Glen Elliott of Children’s Health Council leads clinical research for ... ... 16, 2010 -- Autism is an exceptionally complex illness. Autism ... in addition to restricted, repetitive behaviors. Once considered quite rare, ... diagnosed with the illness, making it a common developmental disability. ...
(Date:3/16/2010)... the best selling skin brightener, has now introduced anti aging ... complete skin care formula. , ... ... ingredients to make SkinBright the most complete skin brightener available. ... scars and uneven skin tone are fading into history with ...
(Date:3/16/2010)... (EDS) announces the introduction of the SafeSiders Glide Path ... effortless endodontic instrumentation, the SafeSiders glide path instruments are ... ... (PRWEB) March 16, 2010 ... of the SafeSiders Glide Path Kit. Designed specifically to ...
Breaking Medicine News(10 mins):Health News:Minnesota Coalition for Kids Health Coverage Launches HealthyKidsMN.org 2Health News:Minnesota Coalition for Kids Health Coverage Launches HealthyKidsMN.org 3Health News:Minnesota Coalition for Kids Health Coverage Launches HealthyKidsMN.org 4Health News:Minnesota Coalition for Kids Health Coverage Launches HealthyKidsMN.org 5Health News:Tahitian Noni Juice Is Now Tahitian Noni Original Bioactive Beverage 2Health News:Autism Research Study Announced By Children's Health Council 2Health News:Best Selling, Non Toxic Skin Brightener Does the Job Using Safe, Healthy Ingredients and Introduces New Anti Aging Ingredients 2
... YORK, Oct. 8 Bristol-Myers Squibb Company,(NYSE: BMY ... 2007 on,Thursday, October 25. During a conference call on ... reviewed and company executives will,address inquiries from investors and ... to listen to a live,webcast of the call at ...
... Pet Partners Joins Forces with 130-Year-Old Organization, ... to advance its,human-animal bond initiative, the American ... Partners to offer direct services in animal-assisted,activities ... Pet,Partners becomes a program of American Humane, ...
... Steel (NYSE:,AKS) said today that it has reached agreement ... to settle a lawsuit stemming from the company,s,initiatives in ... order to,improve its competitiveness. The company said the ... terms of the agreement, AK Steel will,transfer all of ...
... N.J., Oct. 8 NPS Pharmaceuticals,Inc. (Nasdaq: ... O,Callaghan as,senior vice president and chief commercial officer, ... the NPS executive team, Mr. O,Callaghan will be,responsible ... business,development activities, including the commercial development of NPS,s,late-stage ...
... Nashville-based Aegis has been,chosen by Community Medical ... identifies the specific health-related needs of,local employees ... programs with the appropriate individuals. The program ... Center and Fresno,Heart & Surgical Hospital. ...
... NEW YORK, Oct. 8 Health Management Systems,Inc. ... business of Peer Review,Systems, Inc. d/b/a/ Permedion, an ... in Westerville, Ohio. With this,acquisition, HMS augments its ... offerings for state Medicaid agencies and,managed care organizations. ...
Other Medicine News:Health News:American Humane Association Adds Direct Services in Animal-Assisted Activities and Therapy 2Health News:American Humane Association Adds Direct Services in Animal-Assisted Activities and Therapy 3Health News:NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer 2Health News:Aegis Selected by Community Medical Centers to Bring New Employer-Focused Wellness Program to California's Central Valley 2Health News:HMS Acquires Permedion to Expand Clinical Review Capabilities 2
(Date:3/15/2010)... March 15 Abbott (NYSE: ... the first 101 patients enrolled in the second phase ... vascular scaffold (BVS), under clinical investigation in Europe ... need for repeat procedures (ischemia-driven target lesion revascularization) and ... (MACE(1) rate of 2.0 percent) at 30 days. These ...
(Date:3/15/2010)... March 15 Otix Global, Inc. (Nasdaq: OTIX ), announced ... with Silicon Valley Bank.  The amendment extends the term one additional year to ... which allows the Company to obtain additional funds if necessary. , ... ... ...
(Date:3/14/2010)... ATLANTA , March 14 ... needs of cardiology service lines at the 59th ... Cardiology (ACC), March 14-16 in ... to excellence, Siemens empowers its customers with the ... of cardiology, and help them meet their strategic ...
Breaking Medicine Technology:Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology 2Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology 3Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology 4Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology 5Otix Global, Inc. Extends Term of Loan and Security Agreement With Silicon Valley Bank 2Otix Global, Inc. Extends Term of Loan and Security Agreement With Silicon Valley Bank 3Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 2Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 3Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 4Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 5Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 6Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 7Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 8Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 9Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 10Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 11Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 12Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 13Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 14FDA Approves Lillys ZYPREXA 28R 29 RELPREVV 28TM 29 for Treatment of Schizophrenia in Adults 6947 1FDA Approves Lillys ZYPREXA 28R 29 RELPREVV 28TM 29 for Treatment of Schizophrenia in Adults 6947 2FDA Approves Lillys ZYPREXA 28R 29 RELPREVV 28TM 29 for Treatment of Schizophrenia in Adults 6947 3FDA Approves Lillys ZYPREXA 28R 29 RELPREVV 28TM 29 for Treatment of Schizophrenia in Adults 6947 4FDA Approves Lillys ZYPREXA 28R 29 RELPREVV 28TM 29 for Treatment of Schizophrenia in Adults 6947 5FDA Approves Lillys ZYPREXA 28R 29 RELPREVV 28TM 29 for Treatment of Schizophrenia in Adults 6947 6FDA Approves Lillys ZYPREXA 28R 29 RELPREVV 28TM 29 for Treatment of Schizophrenia in Adults 6947 7FDA Approves Lillys ZYPREXA 28R 29 RELPREVV 28TM 29 for Treatment of Schizophrenia in Adults 6947 8CPG International Launches a New Generation of VYCOM 6943 1Half of U S Kids With Mental Issues Are Getting Help 63212 1Half of U S Kids With Mental Issues Are Getting Help 63212 2Half of U S Kids With Mental Issues Are Getting Help 63212 3
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of digoxin in human serum or plasma. Emit 2000 assays are designed for use with most chem...
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... At Akers, our ultimate goal is ... early detection and immediate treatment. Each year ... suffer and die from late detection or ... lives and cripple nations., ,By developing, manufacturing ...
Medicine Products: